CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases 2019

Biocon  /  News – Posts  /  Press Releases  /  Press Releases 2019

Biocon Q2FY20 Earnings Revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3%
  • Wed, 23-Oct-2019
  • Posted by: BIOCON
No Comments

Biocon Biologics & Just – Evotec Biologics Sign Licensing Deal for a Biosimilar Asset
  • Thu, 10-Oct-2019
  • Posted by: BIOCON
No Comments

Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia
  • Thu, 03-Oct-2019
  • Posted by: BIOCON
No Comments

Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs
  • Thu, 26-Sep-2019
  • Posted by: BIOCON
No Comments

Biocon Biologics Expands its R&D Footprint Through Acquisition
  • Tue, 24-Sep-2019
  • Posted by: BIOCON
No Comments

Biocon Licenses Three Generic Formulation Products to China Medical System Holdings
  • Thu, 12-Sep-2019
  • Posted by: BIOCON
No Comments

Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
  • Thu, 22-Aug-2019
  • Posted by: BIOCON
No Comments

Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
  • Thu, 01-Aug-2019
  • Posted by: BIOCON
No Comments

Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr
  • Thu, 25-Jul-2019
  • Posted by: BIOCON
No Comments

Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers
  • Wed, 22-May-2019
  • Posted by: BIOCON
No Comments

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2024, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>